| You are here: Home: BCU 9|2003 - Supplement : Case 4: From the practice of David M Mintzer, MD: Select publications
Select publications
Capecitabine in the metastatic setting
Biganzoli L et al. Moving forward with capecitabine: A glimpse of the future. Oncologist 2002;7(Suppl 6):29-35. Abstract
Blum J. The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer. Oncologist 2001;6(1):56-64. Abstract
Gradishar WJ. Clinical status of capecitabine in the treatment of breast cancer. Oncology (Huntingt) 2001;15(1 Suppl 2):69-71. Abstract
Jakob A et al. Capecitabine in patients with breast cancer relapsing after high-dose chemotherapy plus autologous peripheral stem cell transplantation--a Phase II study. Anticancer Drugs 2002;13(4):405-10. Abstract
Maher JF, Villalona-Calero MA. Taxanes and capecitabine in combination: Rationale and clinical results. Clin Breast Cancer 2002;2(4):287-93. Abstract
O'Shaughnessy JA et al. Randomized, open-label, Phase II trial of oral capecitabine (Xeloda) vs a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001;12(9):1247-54. Abstract
O'Shaughnessy J. Clinical experience of capecitabine in metastatic breast cancer. Eur J Cancer 2002 Feb;38 Suppl 2:10-4. Abstract
Talbot DC et al. Randomised, Phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 2002;86(9):1367-72. Abstract
HER2 concordance between primary and metastatic breast cancer
Dittadi R et al. Evaluation of HER-2/neu in serum and tissue of primary and metastatic breast cancer patients using an automated enzyme immunoassay. Int J Biol Markers 2001;16(4):255-61. Abstract.
Edgerton SM et al. erb-B (HER-2) and breast cancer progression. Appl Immunohistochem Mol Morphol 2003;11(3):214-21. Abstract
Masood S, Bui MM. Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: An immunohistochemical study. Ann Clin Lab Sci 2000;30(3):259-65. Abstract
Sekido Y et al. Heterogeneous gene alterations in primary breast cancer contribute to discordance between primary and asynchronous metastatic/recurrent sites: HER2 gene amplification and p53 mutation. Int J Oncol 2003;22(6):1225-32. Abstract
Simon R et al. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 2001;93(15):1141-6. Abstract
Tanner M et al. Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. Cancer Res 2001;61(14):5345-8. Abstract
Vincent-Salomon A et al. HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process. Cancer 2002;94(8):2169-73. Abstract
|
